Betulinic Acid Derivatives NVX-207 and B10 for Treatment of Glioblastoma—An in Vitro Study of Cytotoxicity and Radiosensitization

Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid

(2014) Sebastian Fischer et al.   PLoS One

GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death

(2012) Stefanie Enzenmüller et al.   CANCER LETTERS

Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process

(2012) P Gonzalez et al.   CELL DEATH AND DIFFERENTIATION

Towards personalized therapy for patients with glioblastoma

(2011) Katsuyuki Shirai et al.   Expert Review of Anticancer Therapy

Anti-Angiogenic Effects of Betulinic Acid Administered in Nanoemulsion Formulation Using Chorioallantoic Membrane Assay

(2011) Cristina A. Dehelean et al.   Journal of Biomedical Nanotechnology

Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review

(2011) Roger Henriksson et al.   JOURNAL OF NEURO-ONCOLOGY

Suppression of STAT3 and HIF-1 Alpha Mediates Anti-Angiogenic Activity of Betulinic Acid in Hypoxic PC-3 Prostate Cancer Cells

(2011) Jimin Shin et al.   PLoS One

Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions

(2011) Matthias Bache et al.   Radiation Oncology

Betulinic acid, a natural compound with potent anticancer effects

(2010) Franziska B. Mullauer et al.   ANTI-CANCER DRUGS

In vitro anticancer studies of α- and β-d-glucopyranose betulin anomers

(2010) Harish Kommera et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Small structural changes of pentacyclic lupane type triterpenoid derivatives lead to significant differences in their anticancer properties

(2010) Harish Kommera et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma

(2010) Carsten Nieder et al.   MEDICAL HYPOTHESES

Betulinic acid inhibits the expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in human endometrial adenocarcinoma cells

(2010) Ewa Karna et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Defective p53 antiangiogenic signaling in glioblastoma

(2010) B. Berger et al.   NEURO-ONCOLOGY

Betulinic Acid a Radiosensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines

(2010) Christina Eder-Czembirek et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Novel semisynthetic derivatives of betulin and betulinic acid with cytotoxic activity

(2009) Rita C. Santos et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound

(2009) M. Willmann et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Rational Design and Semisynthesis of Betulinic Acid Analogues as Potent Topoisomerase Inhibitors

(2009) Fatma M. Abdel Bar et al.   JOURNAL OF NATURAL PRODUCTS

Synthesis and cytotoxic activity of heterocyclic ring-substituted betulinic acid derivatives

(2008) Vivek Kumar et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Enhancing the Divergent Activities of Betulinic Acid via Neoglycosylation

(2008) Randal D. Goff et al.   ORGANIC LETTERS